Imprecision of high-sensitivity cardiac troponin assays at the female 99th-percentile
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved..
BACKGROUND: An analytical benchmark for high-sensitivity cardiac troponin (hs-cTn) assays is to achieve a coefficient of variation (CV) of ≤ 10.0 % at the 99th percentile upper reference limit (URL) used for the diagnosis of myocardial infarction. Few prospective multicenter studies have evaluated assay imprecision and none have determined precision at the female URL which is lower than the male URL for all cardiac troponin assays.
METHODS: Human serum and plasma matrix samples were constructed to yield hs-cTn concentrations near the female URLs for the Abbott, Beckman, Roche, and Siemens hs-cTn assays. These materials were sent (on dry ice) to 35 Canadian hospital laboratories (n = 64 instruments evaluated) participating in a larger clinical trial, with instructions for storage, handling, and monthly testing over one year. The mean concentration, standard deviation, and CV for each instrument type and an overall pooled CV for each manufacturer were calculated.
RESULTS: The CVs for all individual instruments and overall were ≤ 10.0 % for two manufacturers (Abbott CVpooled = 6.3 % and Beckman CVpooled = 7.0 %). One of four Siemens Atellica instruments yielded a CV > 10.0 % (CVpooled = 7.7 %), whereas 15 of 41 Roche instruments yielded CVs > 10.0 % at the female URL of 9 ng/L used worldwide (6 cobas e411, 1 cobas e601, 4 cobas e602, and 4 cobas e801) (CVpooled = 11.7 %). Four Roche instruments also yielded CVs > 10.0 % near the female URL of 14 ng/L used in the United States (CVpooled = 8.5 %).
CONCLUSIONS: The number of instruments achieving a CV ≤ 10.0 % at the female 99th-percentile URL varies by manufacturer and by instrument. Monitoring assay precision at the female URL is necessary for some assays to ensure optimal use of this threshold in clinical practice.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:125 |
---|---|
Enthalten in: |
Clinical biochemistry - 125(2024) vom: 15. März, Seite 110731 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kavsak, Peter A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.clinbiochem.2024.110731 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368502821 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368502821 | ||
003 | DE-627 | ||
005 | 20240305232401.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240216s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.clinbiochem.2024.110731 |2 doi | |
028 | 5 | 2 | |a pubmed24n1317.xml |
035 | |a (DE-627)NLM368502821 | ||
035 | |a (NLM)38360198 | ||
035 | |a (PII)S0009-9120(24)00025-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kavsak, Peter A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Imprecision of high-sensitivity cardiac troponin assays at the female 99th-percentile |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.03.2024 | ||
500 | |a Date Revised 05.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND: An analytical benchmark for high-sensitivity cardiac troponin (hs-cTn) assays is to achieve a coefficient of variation (CV) of ≤ 10.0 % at the 99th percentile upper reference limit (URL) used for the diagnosis of myocardial infarction. Few prospective multicenter studies have evaluated assay imprecision and none have determined precision at the female URL which is lower than the male URL for all cardiac troponin assays | ||
520 | |a METHODS: Human serum and plasma matrix samples were constructed to yield hs-cTn concentrations near the female URLs for the Abbott, Beckman, Roche, and Siemens hs-cTn assays. These materials were sent (on dry ice) to 35 Canadian hospital laboratories (n = 64 instruments evaluated) participating in a larger clinical trial, with instructions for storage, handling, and monthly testing over one year. The mean concentration, standard deviation, and CV for each instrument type and an overall pooled CV for each manufacturer were calculated | ||
520 | |a RESULTS: The CVs for all individual instruments and overall were ≤ 10.0 % for two manufacturers (Abbott CVpooled = 6.3 % and Beckman CVpooled = 7.0 %). One of four Siemens Atellica instruments yielded a CV > 10.0 % (CVpooled = 7.7 %), whereas 15 of 41 Roche instruments yielded CVs > 10.0 % at the female URL of 9 ng/L used worldwide (6 cobas e411, 1 cobas e601, 4 cobas e602, and 4 cobas e801) (CVpooled = 11.7 %). Four Roche instruments also yielded CVs > 10.0 % near the female URL of 14 ng/L used in the United States (CVpooled = 8.5 %) | ||
520 | |a CONCLUSIONS: The number of instruments achieving a CV ≤ 10.0 % at the female 99th-percentile URL varies by manufacturer and by instrument. Monitoring assay precision at the female URL is necessary for some assays to ensure optimal use of this threshold in clinical practice | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Female 99th percentile | |
650 | 4 | |a High-sensitivity cardiac troponin | |
650 | 4 | |a Imprecision | |
650 | 4 | |a Upper reference limit | |
650 | 7 | |a Troponin |2 NLM | |
650 | 7 | |a Troponin T |2 NLM | |
650 | 7 | |a Biomarkers |2 NLM | |
700 | 1 | |a Clark, Lorna |e verfasserin |4 aut | |
700 | 1 | |a Arnoldo, Saranya |e verfasserin |4 aut | |
700 | 1 | |a Lou, Amy |e verfasserin |4 aut | |
700 | 1 | |a Shea, Jennifer L |e verfasserin |4 aut | |
700 | 1 | |a Eintracht, Shaun |e verfasserin |4 aut | |
700 | 1 | |a Lyon, Andrew W |e verfasserin |4 aut | |
700 | 1 | |a Bhayana, Vipin |e verfasserin |4 aut | |
700 | 1 | |a Thorlacius, Laurel |e verfasserin |4 aut | |
700 | 1 | |a Raizman, Joshua E |e verfasserin |4 aut | |
700 | 1 | |a Tsui, Albert |e verfasserin |4 aut | |
700 | 1 | |a Djiana, Rose |e verfasserin |4 aut | |
700 | 1 | |a Chen, Michael |e verfasserin |4 aut | |
700 | 1 | |a Huang, Yun |e verfasserin |4 aut | |
700 | 1 | |a Haider, Ali |e verfasserin |4 aut | |
700 | 1 | |a Booth, Ronald A |e verfasserin |4 aut | |
700 | 1 | |a McCudden, Chris |e verfasserin |4 aut | |
700 | 1 | |a Yip, Paul M |e verfasserin |4 aut | |
700 | 1 | |a Beriault, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Blank, David |e verfasserin |4 aut | |
700 | 1 | |a Fung, Angela W S |e verfasserin |4 aut | |
700 | 1 | |a Taher, Jennifer |e verfasserin |4 aut | |
700 | 1 | |a St-Cyr, Julie |e verfasserin |4 aut | |
700 | 1 | |a Sharif, Sameer |e verfasserin |4 aut | |
700 | 1 | |a Belley-Cote, Emilie |e verfasserin |4 aut | |
700 | 1 | |a Abramson, Beth L |e verfasserin |4 aut | |
700 | 1 | |a Friedman, Steven M |e verfasserin |4 aut | |
700 | 1 | |a Cox, Jafna L |e verfasserin |4 aut | |
700 | 1 | |a Sivilotti, Marco L A |e verfasserin |4 aut | |
700 | 1 | |a Chen-Tournoux, Annabel |e verfasserin |4 aut | |
700 | 1 | |a McLaren, Jesse |e verfasserin |4 aut | |
700 | 1 | |a Mak, Susanna |e verfasserin |4 aut | |
700 | 1 | |a Thiruganasambandamoorthy, Venkatesh |e verfasserin |4 aut | |
700 | 1 | |a Scheuermeyer, Frank |e verfasserin |4 aut | |
700 | 1 | |a Humphries, Karin H |e verfasserin |4 aut | |
700 | 1 | |a Worster, Andrew |e verfasserin |4 aut | |
700 | 1 | |a Ko, Dennis |e verfasserin |4 aut | |
700 | 1 | |a Aakre, Kristin M |e verfasserin |4 aut | |
700 | 1 | |a Mills, Nicholas L |e verfasserin |4 aut | |
700 | 1 | |a Jaffe, Allan S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical biochemistry |d 1970 |g 125(2024) vom: 15. März, Seite 110731 |w (DE-627)NLM000001988 |x 1873-2933 |7 nnns |
773 | 1 | 8 | |g volume:125 |g year:2024 |g day:15 |g month:03 |g pages:110731 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinbiochem.2024.110731 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 125 |j 2024 |b 15 |c 03 |h 110731 |